Randomized Double-blind Study Of Kunxian Capsule In The Treatment Of Progressive Psoriasis Vulgaris

Objective To evaluate the efficacy and safety of Kunxian Capsule in the treatment of advanced psoriasis vulgaris.Methods According to the predetermined inclusion and exclusion criteria,60 patients were randomly divided into the Kunxian capsule group and the placebo group.The PASI,PGA,DLQI,and VAS scores were used to compare and evaluate the drug efficacy.The liver and kidney function and blood routine were also measured.Statistical comparisons were made to evaluate their safety,and the incidence of adverse reactions and treatment measures were recorded.Furthermore,it provides a reliable reference for the application of Kunxian capsule in clinical practice.Results There were significant differences in the proportion of PASI 50,PASI 75,and PASI 90 between the two groups after treatment(P<0.05).The proportion of PASI 50,PASI 75,and PASI 90 in the treatment group was 74.1%,29.6%,and 14.8%.The ratio of PASI 50,PASI 75,and PASI 90 was higher than that in the control group.It can be seen that the efficacy of Kunxian Capsule in the treatment of stage psoriasis vulgaris is significantly different from placebo.Comparing the alanine aminotransferase(ALT)and aspartate aminotransferase(AST)in the treatment group and the control group,it was found that there was no significant difference in ALT and AST between the two groups before and after treatment.Conclusion Kunxian Capsule has satisfactory curative effect on the treatment of psoriasis vulgaris.It has good safety and no obvious side effects.